Effects of antidiabetic drugs on mortality risks in individuals with type 2 diabetes: A prospective cohort study of UK Biobank participants

Elisa Araldi¹-², Catherine R. Jutzeler ³, Michael Ristow¹,⁴*

¹Energy Metabolism Laboratory, Institute of Translational Medicine, Swiss Federal Institute of Technology (ETH) Zürich, Schwerzenbach, CH-8603, Switzerland;
²Center for Thrombosis and Hemostasis and Preventive Cardiology and Preventive Medicine, Center for Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, D-55131, Germany;
³Biomedical Data Science Lab, Institute of Translational Medicine, Swiss Federal Institute of Technology (ETH) Zürich, CH-8008, Switzerland;
⁴Institute of Experimental Endocrinology, Charité Universitätsmedizin Berlin, Humboldt University, Berlin, D-10117, Germany

* michael.ristow@charite.de

Abstract

Objective: To investigate the mortality risk linked to prescription of different anti-diabetic medication classes.

Design: Prospective population-based study.

Setting: UK Biobank.

Participants: 410 389 of the 502 536 participants in UK Biobank with covariate data, clinical and prescription records were included in the analyses, 43 610 of which had been diagnosed type 2 diabetes (T2D). A nearest neighbour covariate matching (NNCM) algorithm based on covariates with relevant effects on survival was applied to match cohorts of anti-diabetic medication class users to minimally differing control cohorts, either with a T2D diagnosis or without. Kaplan Meier estimates and Cox proportional models were used to evaluate survival differences and hazard ratio between drug classes and controls.

Main outcome measures: All-cause mortality and causes of death.

Results: 13667 (3.3%) individuals died during a median of 12.2 years of follow-up. After applying NNCM, participants with T2D on metformin (average hazard ratio 0.39, 95% confidence interval 0.31 to 0.49) or SGLT2I (average hazard ratio 0.58, 95% confidence interval 0.36 to 0.93) have an increased survival probability compared to matched individuals with T2D. When compared to matched individuals without T2D, the survival probability of individuals with T2D increases only if prescribed SGLT2I (average hazard ratio 0.31, 95% confidence interval 0.19 to 0.51). NNCM-based analysis of matched individuals with T2D on both SGLT2I and metformin versus metformin only reveals increased survival in the presence of SGLT2I (average hazard ratio 0.29, 95% confidence interval 0.09 to 0.91), also when compared to matched identical individuals without T2D (average hazard ratio 0.05, 95% confidence interval 0.01 to 0.19). All the other anti-diabetic drugs analyzed are either detrimental in prolonging lifespan (insulin, thiazolidinediones, and sulfonylureas), or have no effect (DPP4 inhibitors and GLP1 receptor agonists).

Conclusion: The use of the current first-line anti-diabetic treatment, metformin, or sodium-glucose cotransporter 2 inhibitors (SGLT2I) increases the survival probability compared to matched individuals with diabetes using other anti-diabetic drugs. Only individuals on SGLT2I experience increased survival when compared to individuals without T2D.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Introduction

Several classes of drugs are routinely prescribed for type 2 diabetes mellitus (T2D) management, including the first-line treatment metformin, but also long-/intermediate- and short-acting insulins, sulfonylureas, as well as the more recent dipeptidyl peptidase 4 inhibitors (DPP4I), glucagon-like peptide 1 receptor agonists (GLP1RA), and sodium-glucose cotransporter 2 inhibitors (SGLT2I)\(^1\)\(^2\). These appear to differently affect long-term outcomes, amelioration of T2D-associated comorbidities, and potentially mortality risks\(^3\)\(^-\)\(^6\).

The first and largest multicenter randomised clinical trial (RCT) of long-term outcomes of anti-diabetic drugs, the *UK Prospective Diabetes Study* (UKPDS) observed 5,102 individuals with type-2 diabetes (herein referred to as T2Ds) for a median of 10 years in a prospective manner. While all the available anti-diabetic treatments at the time (namely metformin, sulfonylureas, and different insulins) were more effective than diet to achieve glycemic control, only obese users of metformin showed a decrease in all-cause mortality\(^7\). Additional classes of anti-diabetic medications targeting other molecular pathways have since been developed and clinically tested\(^8\). Several randomised intervention studies have compared the effectiveness of the long-acting insulin glargine, sulfonylureas, GLPRA, SGLT2I and DPP4I in regards to the respective abilities to lower glycated hemoglobin (HbA1c), either in the unstratified diabetic population, or in subgroup of diabetic individuals \(^9\)\(^-\)\(^11\). Findings from other RCTs suggest that DPP4I, GLP1RA, and SGLT2I may have the potential to reduce mortality of T2Ds\(^4\). Nevertheless, such trials have a limited follow-up time, include a lower number of participants, exclude participants with pre-existing malignancies, and cannot compare outcomes with matched individuals without T2D, especially regarding mortalities and causes of death. Since there is still limited consensus on the most effective targeted second- or third-line treatment for T2D without comorbidities, the choice of add-on glucose lowering therapies is widely based on costs and side effect profiles, rather than efficacy or long-term outcomes \(^9\). Assessing changes in healthspan and lifespan driven by anti-
diabetic medications will guide patients and practitioners to more informed choices on second-line anti-diabetic medications, therefore this research endeavour is of utmost clinical importance. We here aim at investigating the effects of the current anti-diabetic drugs on all-cause mortality and causes of death in a large real-world cohort observed for a median of 12.02 years, by comparing T2Ds with different drug regimens, but also in comparison to individuals without T2D.

Results

Type 2 diabetes mortality and causes of death

We obtained data from the National Health Services (NHS) on clinical records and prescription details for 410,389 UK Biobank participants (Fig 1a), and followed the outcomes from the date of recruitment until the present (median of 12.01 years). Out of 410,389 UK Biobank participants, clinical records of 43,610 individuals reported a diagnosis of T2D (Table 1).

As expected 3 12, individuals with T2D (green) had a lower survival probability than individuals without T2D (black) (Fig 1b). Deaths caused by many comorbidities, including neoplasms (2.23% of the individuals with T2D within the study succumb due to neoplasms vs 1.63% in non-diabetic control individuals - herein referred to as nonT2Ds), cardiovascular diseases (1.57% vs 0.57%) and COVID-19 (0.52% vs 0.13%) were more frequently observed in T2Ds than in nonT2Ds (Fig S1a and b, and Supplementary Table 1), also confirming previous findings regarding an increase in mortality from COVID-19 in T2Ds within the UK Biobank cohort13 14.

Specific anti-diabetic medication classes and all-cause mortality
Analysis of medications prescribed reveals that most T2Ds take only one drug class (33.74%), followed by individuals not prescribed any anti-diabetic drugs (31.02%) (Fig S2a). The remaining T2Ds are prescribed up to six drug classes (Fig S2a). There were similar percentages of deaths among the individuals with T2D of all drug regimens, at around 5% (Fig S2b). The most prescribed drug class is metformin (57.45% of T2Ds prescribed), followed by sulfonylureas (16.47%), long/intermediate-acting insulins (14.40%), DPP4I (13.66%), SGLT2I (8.49%), short-acting insulins (6.45%), GLP1RA (4.20%), thiazolidinediones (1.75%), meglitinides (0.12%) and acarbose (0.03%) (Fig S2c). Users of SGLT2I or GLP1RA had by far the lowest percentage of deaths during the study (1.51% and 2.95%) (Fig S2d).

By contrast, sulfonylureas, long/intermediate- or short-acting insulin users had the highest percentage of deaths (7.61%, 10.55%, and 9.10%) (Fig S2d). The most frequently prescribed compound was metformin (Fig S2e), which was also the drug class most commonly prescribed as a unique anti-diabetic therapy (Fig S2f) reflecting its role as a first-line treatment for T2D. Given the limited number of individuals using meglitinides and acarbose, these were not further analysed for considerations of insufficient statistical power.

Application of a Cox multivariate proportional hazard model considering baseline characteristics, lifestyle, and comorbidities, as well as anti-diabetes medication use revealed that metformin (HR 0.74, CI 0.67-0.83), DPP4I (HR 0.63, CI 0.53-0.75), SGLT2I (HR 0.40, CI 0.29-0.56), and GLP1RA (HR 0.55, CI 0.39-0.79) were linked to an increased survival probability (Fig 1c). When comparing Kaplan-Meier estimates of participants diagnosed with T2Ds only, drug users (blue) prescribed metformin, DPP4I, or SGLT2I had an increased survival probability compared to T2Ds not prescribed the individual drug (red) (Fig S3). Of note, and unlike for Cox analyses, Kaplan-Meier estimates do not correct for co-use of other anti-diabetic drugs.
When performing Kaplan-Meier estimates to compare survival probability of T2Ds using the respective compound (blue) to no-T2Ds (black), only SGLT2I users showed improved survival compared non-T2Ds (log-rank P value 0.003) (Fig S3). All other compounds, including metformin (log-rank P value < 0.001), DPP4I (log-rank P value 0.007), and GLP1RA (log-rank P value 0.16) failed to promote survival compared to non-T2D participants not prescribed any of these drugs (Fig S3). Of note, non-T2Ds in this analysis have not been matched to T2Ds for comorbidities or other confounders, nor do Kaplan-Meier estimates correct for co-use of additional anti-diabetic drugs within the T2D cohort.

Differences in anti-diabetic drug class use and age at first drug use require nearest neighbour covariate matching (NNCM)

Clinical availability of anti-diabetic drug classes differs considerably. Accordingly, our analysis revealed that DPP4I, SGLT2I, and GLP1RA have been used for a shorter period of time (median of 3.26, 2.57, and 2.35 years, respectively) than metformin (median of 8.87 years), sulfonylureas (median of 8.19 years), short-acting insulins (median of 11.72 years), long/intermediate-acting insulins (median of 8.14 years), or thiazolidinediones (median of 9.08 years) (Fig S4a). Also, individuals who are first-time users of these newer drugs are on average of higher age (median of 68.66 years for DPP4I, 64.34 for GLP1RA, and 64.47 for SGLT2I) than patients prescribed metformin (61.13), sulfonylureas (62.49), short-acting (57.39), long/intermediate-acting insulins (61.51), or thiazolidinediones (62.97) (Fig S4b). These findings could, at least in part, explain the survival differences depicted in Fig 1 and Fig S3. Therefore, measures to minimise such indication bias, as well as an immortal time bias appear mandatory, which were obtained by applying nearest neighbour covariate matching (or NNCM), a statistical learning method (see Methods and Supplementary Information for details).

SGLT2I and metformin extend lifespan in individuals with type 2 diabetes
After application of NNCM (Fig S5a-b), exposure to drugs was comparable among cohorts (Fig S6), and Kaplan-Meier estimates of survival of T2Ds using the drug of interest show that only users of metformin or SGLT2I had reduced all-cause mortality, when compared to matched T2D users of other drugs (Fig 2a). Drug use- and confounder-corrected Cox proportional multivariate hazard analysis corroborates the findings: metformin (HR 0.40, 95% CI 0.32 to 0.50) and SGLT2I (HR 0.47, 95% CI 0.29 to 0.74) improved the survival of its users of (Fig 2b). Confirming the Kaplan-Meier estimates (Fig 2a), users of sulfonylureas (HR 1.28, 95% CI 1.06-1.55), long/intermediate insulins (HR 1.72, 95% CI 1.36-2.17) and short-acting insulins (HR 1.72, 95% CI 1.16-2.55) had increased mortalities (Fig 2b).

Metformin users compared to T2D matched controls were protected from deaths caused by neoplasms (1.61% vs 3.73% deaths during the study) and cardiovascular disease (1.08% vs 2.81%), while SGLT2I users had fewer deaths by neoplasms (0.71% vs 1.75%) (Fig S7). Both sulfonylureas as well as long/intermediate-acting insulins increased the risk to die from neoplasms and from diseases of the circulatory system. Short-acting insulins did increase the risk to die from cardiovascular diseases but not from neoplasms (Fig S7 and Supplementary Table 2).

**SGLT2I reduce mortality risk compared to matched individuals without type 2 diabetes**

To assess the absolute effect of individual anti-diabetic drugs on all-cause mortality, we matched T2Ds to control nonT2Ds by applying NNCM (Fig S5c-d).

In this analysis, only SGLT2I users had a survival advantage compared to matched nonT2Ds, while users of metformin had lower life expectancy than undiagnosed matched controls (Fig 3a). Of note, both latter findings are already anticipated in the analyses of the unmatched cohorts (Fig S3). Resembling the previous analyses (Fig S3, Fig 2a), sulfonylureas, long/intermediate-acting insulins, and short-acting insulin users had a survival disadvantage compared to matched non-T2D-diagnosed individuals (Fig 3a).
Cox proportional multivariate hazard analysis (Fig 3b) corroborates the positive effect of SGLT2I (HR 0.31, 95% CI 0.19 to 0.51) and DPP4I on survival (HR 0.63, 95% CI 0.49 to 0.79). However, DPP4I failed to reduce mortality in Kaplan-Meier estimates (Fig 3a). By contrast, metformin did not improve survival of its users compared to matched nonT2Ds (HR 0.94, 95% CI 0.84 to 1.07) (Fig 3b). Also, users of SGLT2I (0.61% vs 1.57%) and DDP4I (1.52% vs 2.59%) had significantly fewer deaths from neoplasms (Fig S8), whereas metformin did not exert such reduction. Causes of death for the other drugs are available in Fig S8 and Supplementary Table 3.

Effects of SGLT2I in combination with metformin compared to metformin alone or to individuals without type 2 diabetes

Hence, when compared to nonT2Ds after NCCM, SGLT2I seems to be the most effective drug class to treat T2Ds, followed by DPP4I. However, a significant portion of T2Ds using one of these latter compounds also takes metformin (n=1131 for DPP4I & metformin, n=578 for SGLT2I & metformin), and up to 4 additional other antidiabetic drugs (Fig S2a, c, e). While corrected for different/combined drug use in the Cox analysis (Fig 3b), we nevertheless aimed to quantify the relative effects of such combined therapies. Again, by applying NNCM, we first matched T2Ds using metformin together with either DPP4I or SGLT2I, with T2Ds using metformin only. We next matched the exact same T2Ds using metformin plus either DPP4I or SGLT2I with nonT2Ds. Lastly, we used the exact same matched nonT2Ds to compare them with the exact same T2Ds using metformin only as above.

For DPP4I combined with metformin, no differences were observed in regards to survival by both Kaplan-Meier and Cox analyses (Fig 4a). By contrast, comparison of diabetic SGLT2/metformin users with NNC-matched individuals with T2Ds prescribed metformin only revealed a survival advantage, both by Kaplan-Meier (P = 2.31e-02) as well as Cox analyses (HR
0.29, 95% CI 0.09 to 0.91, P=0.03), for the combined use. Comparing the same SGLT2/metformin users with NNC-matched nonT2D individuals, a strong advantage for SGLT2I/metformin usage was observed for T2Ds (KM P = 2.32e-04; Cox HR 0.058, 95% CI 0.02 to 0.19). Of note, when comparing the matched metformin-only T2D with the same matched nonT2Ds as above, the effect was absent by Kaplan-Meier estimates (P = 1.09e-01), or markedly reduced for the Cox analysis (HR 0.42, 95% CI 0.21 to 0.87) (Fig 4b).

Also taking the findings depicted in Fig 3 into account, these findings independently indicate that SGLT2I, when added to a first-line metformin treatment, extend survival beyond the life expectancy of non-diabetic control individuals, and notably better than metformin does either alone, or with any other antidiabetic co-medication but SGLT2I.

Discussion

Statement of principal findings

Multiple therapeutic options are available for type 2 diabetes. In the current study, the current first line-treatment, the biguanide metformin, was found capable of reducing the mortality of T2Ds when compared to other T2Ds not prescribed metformin (Fig S3, Fig 1c, Fig 2a, Fig 2b). However, and unlike SGLT2I, metformin was unable to reinstate normal (i.e. non-diabetic) life expectancy in T2Ds, as identified by higher mortality rates of T2Ds on metformin compared to nonT2Ds (Fig S3, Fig 3b) in the current study. Moreover, our findings not only identify a reduction in overall mortality risk of T2Ds following SGLT2I prescription compared to T2Ds on drugs other than SGLT2I, but also a reduction of mortality risk compared to nonT2Ds. The analyses also indicate a reduction in cancer-related deaths in SGLT2I users (Fig S7, Fig S8).
SGLT2I were linked to increased survival probability in both Kaplan-Meier (Fig 3a) and Cox (Fig 3b) analyses; also, DPP4I were linked to increased survival in the Cox (Fig 3b) analysis only, however showed no mortality advantage in the Kaplan-Meier analysis (Fig 3a). Hence, when compared to non-T2Ds, SGLT2I seems to be the most effective drug class to treat T2Ds, followed by DPP4I. However, a significant portion of T2Ds using one of these latter compounds also take metformin (n=578 for SGLT2I & metformin, n=1131 for DPP4I & metformin). Therefore, we have performed subgroup analyses to directly compare the effect of users of metformin and SGLT2I or DPP4I against metformin alone. While adding DPP4I to metformin had no effect on survival (Fig 4a), the use of SGLT2I in combination with metformin was able to prolong lifespan in T2D patients compared to the ones using metformin alone, and SGLT2I and metformin users had a considerable survival advantage compared to no-T2D or to metformin only users compared to no-T2D (Fig 4b).

Earlier anti-diabetic drug classes (namely sulfonylureas, insulins, and thiazolidinediones) had either a pronounced negative impact on mortality risks, or showed no difference in survival, in accordance with what has been observed in previous studies.5 17.

Strengths and weaknesses of the study

This study uses data from the UK Biobank, a prospective study, and an innovative statistical learning algorithm, namely NNCM with priority matching of lifespan-modulating covariates, to compare longevity of real-world users of commonly prescribed anti-diabetic drug classes. Due to the inclusion of health records and outcomes, it provides the means to compare the mortality rates of a large number of T2D patients prescribed different medication classes, over a long observation time, and also against individuals without T2D.

For reasons of statistical power, we here report survival analyses among classes of anti-diabetic medications, rather than of individual compounds, under the implicit assumption that compounds
within each anti-diabetic drug class have similar mechanisms of action, and therefore comparable
effects on longevity. However, differences in bioavailability, target affinity and off-target effects of
individual compounds in the same drug class might influence long-term outcomes, and the effect
of each drug may be lost or overstated when analysed in combination with other medications in
the same drug class.

Although our analysis includes up to 15 years of observations for some individuals, the
exposure time of the most recently introduced medications (namely SGLT2I, GLR1RA, and
DPP4I) is considerably shorter than for other medications. However, this difference is also being
corrected for in the NNCM (Fig S5), and should hence not affect the differences in mortality of
the two drug classes where effects superior to metformin are being detectable already (SGLT2I
and possibly DPP4I). However, a longer follow-up time in the UK Biobank will increase the power
of this analysis and might reveal statistically significant effects also of the only more recent anti-
diabetic medication without relevant impact on survival probability in the current analysis, namely
GLP1RA (Figs. 2a and b, 3a and b).

Another potential limitation concerns both the Cox covariate corrections as well as the
NNCM strategy, which are both based on characteristics quantified at UK Biobank recruitment
and do not fully consider clinical events, nor changes in physical and lifestyle characteristics
throughout the observation period. Therefore, treatment-independent changes in baseline
characteristics but also other unmeasured confounders, which might affect treatment choice or
contribute to all-cause mortality, cannot and hence are not accounted for in neither covariate
correction nor NNCM. As commonly applied elsewhere, we have assumed that the distribution of
unmeasured confounders is equal in controls and treated individuals throughout time, similarly to
what is customary in RCTs, where these limitations likewise apply.
**Strengths and weaknesses in relation to other studies, discussing important differences in results**

The mortality-reducing capability of metformin observed in the current study is supported by long-standing evidence from the UKPDS study indicating that metformin reduces mortality in obese T2Ds \(^7\). T2Ds prescribed metformin had similar survival to matched non-T2Ds not prescribed anti-diabetic medications, following covariate corrected Cox analysis (**Fig 3b**). These data reassuringly support the previous findings that metformin does not harm, and show that this compound indeed restores life expectancy to the extent of non-T2D-diagnosed individuals. Hence, the use of metformin as the first-line monotherapy for T2D is justified due to its proven limited side effects, weight neutrality, and low costs \(^8\).

SGLT2I have been clinically available for a shorter time, compared to other anti-diabetic drug classes (in this study, median prescription length: 2.57 years, longest prescription: 7.83 years, patient-years: 12096). SGLT2I have been evaluated in several RCTs, including the EMPA-REG OUTCOME study \(^18\), where empagliflozin was applied in addition to standard treatment (most frequently metformin) to T2Ds with pre-existing cardiovascular disease, to observe a lower rate of death from any cause in the empagliflozin group. Subsequent RCTs also testing other gliflozins on different subgroups of T2Ds very consistently confirmed and extended such findings on reduction in all cause-mortality of T2Ds following application of SGLT2I, all in the presence of metformin \(^4,19-21\).

Moreover, we cannot exclude the possibility that SGLT2I or DPP4I, while showing advantageous effects over metformin in the current and previous analyses \(^4,19,20\), may opposingly exert negative impact on long-term survival probability after extended use \(^22,23\).

**Meaning of the study: possible explanations and implications for clinicians and policymakers**
The key results of this study encourage clinicians to consider both metformin and SGLT2I as independent or combined first-line treatment(s) in the management of T2D. Moreover, the study prompts to investigate the health benefits of SGLT2I also in light of its previously unknown anti-cancer effects. One recent RCT has tested metformin, DPP4I, and SGLT2I separately in drug-naïve T2Ds, to find that all three drugs lowered HbA1c levels, with metformin being most effective in regards to the latter, but only the SGLT2I dapagliflozin in the absence of metformin lowers insulin levels and body mass, which could explain its ability to reduce cancer-related deaths.  

**Unanswered questions and future research**

The mechanisms behind SGLT2I’s ability to extend lifespan are not limited to their glucose-lowering abilities or improvement of cardiovascular outcomes, and remain to be further explored. The reduction of mortality via SGLT2I application cannot be fully explained by the limited improvement of cardiovascular risk factors, despite the fact that the key SGLT2I trials lasted up to 4.2 years (DECLARE-TIMI 58: 218 weeks; EMPA-REG OUTCOME: 161 weeks; CREDENCE: 136 weeks; CANVAS: 126 weeks). Insofar it is interesting that our current findings not only identify a reduction in overall mortality risk of T2Ds following SGLT2I, but also indicate a reduction in cancer-related deaths when compared to T2Ds on drugs other than SGLT2I (Fig S7) as well as nonT2Ds (Fig S8). These findings might hint at an additional advantage of SGLT2I use also for the improvement of survival in oncological patients with or even without T2D, since most RCTs on SGLT2I have excluded individuals with pre-existing cancer diagnoses from participation, but this hypothesis needs to be tested formally with an ad hoc RCT. Also, these findings suggest to use specific anti-diabetic compounds as a preventative strategy to promote healthspan not only in T2Ds, but also in middle-aged to elderly nonT2Ds. This has
been previously hypothesized for metformin as well as for SGLT2I, while controlled interventional data are pending.

Methods

Datasets

The UK Biobank is a prospective study that recruited 502,611 participants aged between 38 and 73 years from 22 sites across the UK with baseline measures collected between 2006 and 2010. Data have since been linked to hospital, prescription and mortality records. We used the British National Formulary codes 6.1.1.X (insulins) and 6.1.2.X (antidiabetic drugs) to select anti-diabetic drugs from prescription records, and classified these according to ATC classification (A10B).

More details can be found in Supplementary Information (refers also to subsequent Methods sections).

Criteria for Inclusion and Exclusion of Participants

Only participants with clinical data and prescription data were included in the study. Individuals that died of accidental causes or self-inflicted deaths (ICD10 codes starting with O, Q, S, T, V, W, Y, X) were excluded from the analysis (Fig 1a). Characteristics of all individuals included into the analyses can be found in Table 1. T2Ds had at least one ICD10 diagnosis starting with E11; nonT2Ds were selected by the absence of such diagnoses, and also by the absence of type 1 diabetes (ICD10 code E10).

Observation Time, Length of Exposure, and End Points
The individuals were followed from recruitment (2006-2010) until censoring time (March 20th, 2021), for a median of 12.02 years. The primary endpoint was death from any cause, except self-inflicted death and death by accidents. No secondary endpoints were considered.

**Nearest Neighbour Covariate Matching (NNCM) Strategy**

T2D-diagnosed subjects prescribed the drug of interest were individually matched either with T2D subjects not prescribed that drug (T2Ds with drug vs. T2Ds without drug), or with nonT2Ds (T2Ds with drug vs nonT2Ds without drug). In the latter case, T2D diagnosis by definition was used as a sorting variable.

Each individual of the T2D with drug cohort was paired to the most similar individual of the T2D without drug or non-T2D-diagnosed cohort with an unsupervised nearest neighbours algorithm matching on covariate distances (*Fig S5* and *Supplementary Information*) 29-31.

A Cox proportional hazard multivariate model was used to determine within each cohort comparison the covariates contributing mostly to the observed mortality (having log(HR) > 0.05 or log(HR) < -0.05), hereafter referred to as priority-matched covariates (*Fig S5*), which were given a greater matching weight by the algorithm.

**Survival analyses: General Remarks**

Censoring time was independent of the event time for all individuals, and there were no known dependent competing risks, therefore survival analysis was carried out with Kaplan-Meier survival estimates and Cox proportional hazard models. Age at recruitment, sex, genetic principal components 1-20 (as proxy for population ethnic diversity), lifestyle factors (BMI, smoking, alcohol intake, physical exercise, Townsend deprivation index, sleep duration), comorbidities
(fractured/broken bones, cancer, cardiovascular disease, blood clots, deep vein thrombosis [DVT], bronchitis, emphysema, other serious medical condition), and use of diabetic drugs, were exogenous variables for Cox proportional hazard model. Of note, Cox analysis, by definition, included correction for antidiabetic drugs used by T2Ds. Detailed survival analyses for the observational cohort and NNCM can be found in **Supplementary Information**.

**Cause of Death Analysis**

Primary causes of death in ICD-10 notation were available from death records of the UK Biobank (data field 40001) and annotated into main disease chapters according to ICD-10 (version 2019, icd.who.int/browse10/2019/en). Deviations from the proportion of expected versus observed deaths of a certain cause within the case-control cohorts were calculated with a chi-squared test.

**Code Availability**

All the Analyses, Figures and Tables were created with Python3.7 and supporting libraries. Custom code for the analyses will be made available upon publication at [https://github.com/araldi/Anti-diabetics-and-survival-in-UKBB](https://github.com/araldi/Anti-diabetics-and-survival-in-UKBB).

**Patient and public involvement**

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

**Footnotes**
Contributors

EA and MR designed the study. EA conducted the statistical analysis. EA and MR wrote the first draft. EA, CRJ, and MR critically revised the manuscript. MR is the guarantor of the manuscript and accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Ethics approval

UK Biobank has obtained ethics approval from the North West Multi-Centre Research Ethics Committee (approval number: 11/NW/0382) and has obtained informed consent from all participants.

Transparency statement

The manuscript’s guarantor (MR) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Competing interests

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish government, and Northwest Regional Development Agency; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Data sharing
Funding

UK Biobank was established by the Wellcome Trust, Medical Research Council, Department of Health, Scottish government, and Northwest Regional Development Agency. It has also had funding from the Welsh assembly government and the British Heart Foundation. The analyses in this study were funded by the Swiss National Science Foundation (31003A_176127 and 310030_204511 to M.R., PZ00P3_186101 to C.R.J.), the ETH Career Seed Grant (1-007724 SEED-11 to E.A.), and the Holcim Stiftung (to E.A.).

Acknowledgments

We thank UK Biobank participants. This research has been conducted using the UK Biobank Resource 48008.

Copyright/license for publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.
References:

1. World Health Organisation WHO. WHO model list of essential medicines (22nd list). 2021


Legends to Figures

Fig 1: Cohort structure and unmatched survival probabilities depending on diagnosis of type 2 diabetes and anti-diabetic drug classes used

a, Flowchart for inclusion/exclusion criteria in the UK Biobank cohort. Type 2 diabetes (T2D) diagnoses and anti-diabetic medication prescriptions were retrieved from general practice (GP) clinical records and primary care datasets in National Health Service (NHS) records. T2D diagnoses have ICD10 code starting with E11. Anti-diabetic medications were selected from brand name and compounds classified in British National Formulary as anti-diabetic, class 6.1.1 (insulins) and class 6.1.2 (anti-diabetic drugs).

b, Kaplan-Meier curve of survival probability of individuals diagnosed with T2D (T2Ds) or not T2D-diagnosed controls (nonT2Ds). P value obtained from log-rank test.

c, Forest plot of Cox proportional hazard multivariable modelling on overall survival. Shown are the natural logarithm of the hazard ratio (HR) and bars represent 95% confidence interval of anti-diabetic drug classes used.

Fig 2: Survival probabilities and causes of death of individuals with type 2 diabetes using a specific drug class compared to NNC-matched individuals with type 2 diabetes using any other drug class

a, Kaplan-Meier curves of survival probabilities of individuals diagnosed with T2D and either using specific anti-diabetic drug classes (cyan) or matched individuals not prescribed the specific drug class (pink). P values shown are calculated with log-rank test.

b, Forest plot of Cox proportional hazard multivariable modelling on overall survival in individuals diagnosed with T2D and prescribed the specific drug class, and matched individuals diagnosed with T2D but not
prescribed the specific drug class. Shown is the hazard ratio (HR) and bars represent 95% confidence intervals of each anti-diabetic drug class.

**Fig 3: Survival probabilities and causes of death of individuals with type 2 diabetes using a specific drug class compared to NNC-matched individuals without diagnosis of type 2 diabetes**

*a*, Kaplan-Meier curves of survival probabilities of individuals diagnosed with T2D using specific anti-diabetic drug classes (cyan) or matched individuals not diagnosed with T2D (black). P values shown are calculated with log-rank test. **b**, Forest plot of Cox proportional hazard multivariable modelling on overall survival in individuals diagnosed with T2D and prescribed the specific drug class, and matched individuals not diagnosed with T2D. Shown is the hazard ratio (HR) and bars represent 95% confidence interval of each anti-diabetic drug class.

**Fig 4: Subgroup analysis of DPP4I or SGLT2I combined with metformin with either metformin alone or matched nonT2Ds**

*a*, Kaplan-Meier survival probability (left) and Cox proportional hazard multivariable modelling (right) of the reference group of individuals diagnosed with T2D using DPP4I and metformin (gold), NNC-matched individuals using metformin only (purple), and NNC-matched individuals without T2D diagnoses (black). Shown for Cox proportional hazard model is the hazard ratio (HR) and bars represent 95% confidence interval of each anti-diabetic drug class. **b**, Kaplan-Meier survival probability (left) and Cox proportional hazard multivariable modelling (right) of the reference group of individuals diagnosed with T2D using SGLT2I and metformin (gold), NNC-matched individuals using metformin only (purple), and NNC-matched individuals without T2D diagnoses (black). Shown for Cox proportional hazard model is the hazard ratio (HR) and bars represent 95% confidence interval of each anti-diabetic drug class.
Supplementary Figures

Supplementary Fig 1. a, Causes of death divided by ICD10 chapters for deceased individuals in the UK Biobank with (T2Ds) or without (Not T2Ds) T2D diagnoses. Deaths by accident or self-inflicted (ICD10 codes O, Q, S, T, V, W, X, Y) were excluded from analysis. P values obtained by chi-squared contingency test. b, Most frequent causes of death in the whole dataset divided by ICD10 subchapters for deceased individuals in the UK Biobank with (T2Ds) or without (Not T2Ds) T2D diagnoses. Deaths by accident or self-inflicted (ICD10 codes O, Q, S, T, V, W, X, Y) were excluded from analysis. P values obtained by chi-squared contingency test.

Supplementary Fig 2. a-b, Percentage (and number) of individuals diagnosed with T2D and using a combinations of anti-diabetic drug classes (a) and percentage (and number) of deaths within each drug regimen (b). c-d, Percentage (and number) of individuals diagnosed with T2D and using a specific anti-diabetic drug class (c) and percentage (and number) of deaths within users of a specific compound class (d). e, Number of T2D-diagnosed individuals in the UK Biobank using anti-diabetic compounds. Prescriptions for brand name compounds are included in the counts of the corresponding generic compound. f-g, Percentage (and number) of users of anti-diabetic drug classes used as the only anti-diabetic medications in UK Biobank individuals (f) and corresponding death rates (and number of deaths) (g). h, Individuals using anti-diabetic drugs and not diagnosed with type 2 diabetes (ICD10 code E11). These individuals were excluded from all the analyses.
Supplementary Fig 3. Kaplan-Meier curves of survival probability of T2Ds either using a specific anti-diabetic drug class (blue) or not using this drug class (red), and non-T2Ds (black). P values shown are for each comparison calculated with log-rank test.

Supplementary Fig 4. a, Age at first use of anti-diabetic compounds classes. Mean is represented by black dashed line, standard deviation by grey dashed line. Each bar represents an interval of 5 years. Data obtained from NHS prescription data was cross-referenced with UK Biobank recruitment data.

b, Length of use of anti-diabetic compounds classes at the event (death or censoring). Mean is represented by black dashed line, standard deviation by grey dashed line. Each bar represents an interval of 2 years. Data obtained from NHS prescription data cross-referenced with UK Biobank recruitment data.

Supplementary Fig 5. a, Cox proportional hazard multivariate modelling of survival in T2D-diagnosed individuals. Vertical fine dashed lines represent respectively log(HR) of -0.05 and of 0.05. Orange-coloured variables are responsible for a significant absolute change in log(HR) greater than 0.05, therefore identified as priority-matched covariates for this cohort. b, Strategy to match T2D-diagnosed individuals prescribed the drug of interest with control T2D-diagnosed individuals prescribed other drugs. The priority-matched covariates were identified from Panel A.

c, Cox proportional hazard multivariate modelling of survival in non-T2D-diagnosed individuals and T2D-diagnosed individuals. Vertical fine dashed lines represent respectively log(HR) of -0.05 and of 0.05. Blue-coloured variables are responsible for a significant change in log(HR) greater than 0.05, therefore identified as priority-matched covariates for this cohort. d, Strategy to match T2D-diagnosed individuals prescribed the drug of interest with control not T2D-
diagnosed individuals. The priority-matched covariates were identified from Panel C. e-f,
Formulae of distance matrices for continuous (e) or binary (f) priority-matched covariates.

**Supplementary Fig 6:** Accuracy of Nearest Neighbour Covariate Matching (NNCM) of T2D-diagnosed individuals treated with the drug of interest matched with control T2D-diagnosed individuals using other drugs or none. Matched variables: age at recruitment [years], and age at first drug use [years]. Other characteristics calculated from matched variables: Length of drug use [years] and years between recruitment and first drug use.

**Supplementary Fig 7.** a, Causes of death divided by ICD10 chapters for T2D-diagnosed individuals prescribed metformin, DPP4I, SGLT2I (all blue) and matched T2D-diagnosed individuals prescribed other drugs (red). Data are represented as proportion of deaths within each cohort. Deaths by accident or self-inflicted (ICD10 codes O, Q, S, T, V, W, X, Y) were excluded from analysis. P values obtained by chi-squared contingency test.

b, Causes of death divided by ICD10 chapters for T2D-diagnosed individuals prescribed sulfonylureas, long/intermediate-acting insulins, GLP1R agonists, short-acting insulins, thiazolidinediones (all blue) and matched T2D-diagnosed individuals prescribed other drugs (red). Data are represented as proportion of deaths within each cohort. Deaths by accident or self-inflicted (ICD10 codes O, Q, S, T, V, W, X, Y) were excluded from analysis. P values obtained by chi-squared contingency test.

c, Most frequent causes of death by ICD10 subchapters for T2D-diagnosed individuals prescribed metformin, DPP4I, SGLT2I (all blue) and matched T2D-diagnosed individuals prescribed other drugs (red). Data are represented as proportion of deaths within each cohort. Deaths by accident or self-inflicted (ICD10 codes O, Q, S, T, V, W, X, Y) were excluded from analysis. P values obtained by chi-squared contingency test.
**Supplementary Fig 8.**

- **a,** Causes of death divided by ICD10 chapters for T2D-diagnosed individuals prescribed metformin, DPP4I, SGLT2I (all blue) and for matched not T2D-diagnosed individuals (black). Data are represented as proportion of deaths within each cohort. Deaths by accident or self-inflicted (ICD10 codes O, Q, S, T, V, W, X, Y) were excluded from analysis. P values obtained by chi-squared contingency test.

- **b,** Causes of death divided by ICD10 chapters for T2D-diagnosed individuals prescribed sulfonylureas, long/intermediate-acting insulins, GLP1R agonists, short-acting insulins, thiazolidinediones (all blue) and for matched not T2D-diagnosed individuals (black). Data are represented as proportion of deaths within each cohort. Deaths by accident or self-inflicted (ICD10 codes O, Q, S, T, V, W, X, Y) were excluded from analysis. P values obtained by chi-squared contingency test.

- **c,** Most frequent causes of death by ICD10 subchapters for T2D-diagnosed individuals prescribed metformin, DPP4I, SGLT2I (all blue) and for matched not T2D-diagnosed individuals (black). Data are represented as proportion of deaths within each cohort. Deaths by accident or self-inflicted (ICD10 codes O, Q, S, T, V, W, X, Y) were excluded from analysis. P values obtained by chi-squared contingency test.

- **d,** Most frequent causes of death by ICD10 subchapters for T2D-diagnosed individuals prescribed sulfonylureas, long/intermediate-acting insulins, GLP1R agonists, short-acting insulins, thiazolidinediones (all blue) and matched not T2D-diagnosed individuals (black). Data are represented as proportion of deaths within each cohort. Deaths by accident or self-inflicted (ICD10 codes O, Q, S, T, V, W, X, Y) were excluded from analysis. P values obtained by chi-squared contingency test.
are represented as proportion of deaths within each cohort. Deaths by accident or self-inflicted
(ICD10 codes O, Q, S, T, V, W, X, Y) were excluded from analysis. P values obtained by chi-
squared contingency test.
Figure 1

502,461 individuals recruited at baseline in the UK Biobank

501,473 individuals after application of exclusion criteria

410,389 individuals with NHS prescription and clinical data available

43,610 individuals diagnosed with type 2 diabetes (ICD10 E11 diagnosis)

366,779 individuals not diagnosed with type 2 diabetes

Exclusion Criteria
988 accidental deaths and suicides excluded (ICD10 codes starting with O, Q, S, T, V, W, X, Y)

Control individuals T2D-diagnosed using other anti-diabetic treatments if taking other drugs, for at least 3 months and until at least 6 months from the last recorded date - either death or censoring

T2D-diagnosed individuals using the drug of interest for at least 3 months and until at least 6 months from the last recorded date - either death or censoring

Control individuals not T2D-diagnosed and not taking any anti-diabetic drugs

NNC Matching T2D-diagnosed drug of interest vs T2D-diagnosed using other treatment(s)

NNC Matching not T2D-diagnosed vs T2D-diagnosed using the drug of interest

Survival analysis on matched cohort of Type 2 Diabetics

T2D-diagnosed using the drug of interest

NNC-matched control T2D-diagnosed using other treatment(s)

T2D-diagnosed using the drug of interest

Survival analysis on matched cohort of not T2D-diagnosed vs T2D-diagnosed using drug of interest

T2D-diagnosed

NNC-matched control not T2D-diagnosed

P = 4.95e-78

Survival Probability

Age [Years]

0.5 0.6 0.7 0.8 0.9 1.0

55 60 65 70 75 80 85 90

T2D-diagnosed (total = 43,610; † = 2,551)

Not T2D-diagnosed (total = 366,779; † = 11,116)

C Anti-Diabetic Drugs
Metformin
Sulfonylureas
DPP4i
Long/Interm.-Acting insulins
SGLT2i
GLP1RA
Short-Acting insulins
Thiazolidinediones

P Values
4.00e-06
4.68e-12
2.17e-07
1.25e-12
1.05e-07
1.19e-03
8.13e-03
6.38e-01
Figure 3

(a) Survival probability for different types of anti-diabetic drugs.

- **Metformin**
  - T2D + Metformin (total = 15,586, \( \dagger = 741 \))
  - No T2D matched controls (total = 15,586, \( \dagger = 512 \))
  - \( P = 9.22e-04 \)

- **Sulfonylureas**
  - T2D + Sulfonylureas (total = 4,472, \( \dagger = 327 \))
  - No T2D matched controls (total = 4,472, \( \dagger = 197 \))
  - \( P = 7.49e-10 \)

- **DPP4 inhibitors**
  - T2D + DPP4 (total = 3,666, \( \dagger = 164 \))
  - No T2D matched controls (total = 3,666, \( \dagger = 101 \))
  - \( P = 1.11e-01 \)

- **Long/Interm.-Acting Insulins**
  - T2D + Long/Interm.-Act. Ins. (total = 2,850, \( \dagger = 254 \))
  - No T2D matched controls (total = 2,850, \( \dagger = 133 \))
  - \( P = 1.15e-09 \)

- **SGLT2i**
  - T2D + SGLT2i (total = 2,299, \( \dagger = 37 \))
  - No T2D matched controls (total = 2,299, \( \dagger = 64 \))
  - \( P = 7.57e-03 \)

- **GLP1RA**
  - T2D + GLP1RA (total = 1,124, \( \dagger = 38 \))
  - No T2D matched controls (total = 1,124, \( \dagger = 57 \))
  - \( P = 9.00e-01 \)

- **Short-Acting Insulins**
  - T2D + Short-Acting Insulins (total = 1,060, \( \dagger = 83 \))
  - No T2D matched controls (total = 1,060, \( \dagger = 30 \))
  - \( P = 2.93e-07 \)

- **Thiazolidinediones**
  - T2D + Thiazolidinediones (total = 479, \( \dagger = 33 \))
  - No T2D matched controls (total = 479, \( \dagger = 11 \))
  - \( P = 9.39e-04 \)

(b) Hazard ratio (HR) with 95% confidence interval (CI) for different anti-diabetic drugs.

- **Anti-Diabetic Drugs**
  - Metformin
  - Sulfonylureas
  - DPP4 inhibitors
  - Long/Interm.-Acting Insulins
  - SGLT2i
  - GLP1RA
  - Short-Acting Insulins
  - Thiazolidinediones

- **P Values**
  - Metformin
    - HR (95% CI): 3.61e-01
    - P Value: 2.35e-03
  - Sulfonylureas
    - HR (95% CI): 1.12e-04
    - P Value: 1.73e-03
  - DPP4 inhibitors
    - HR (95% CI): 2.61e-06
    - P Value: 5.94e-01
  - Long/Interm.-Acting Insulins
    - HR (95% CI): 1.01e-03
    - P Value: 4.01e-01
  - SGLT2i
    - HR (95% CI): 9.39e-04
    - P Value: 3.61e-01
  - GLP1RA
    - HR (95% CI): 7.57e-03
    - P Value: 1.11e-01
  - Short-Acting Insulins
    - HR (95% CI): 7.49e-10
    - P Value: 1.15e-09
  - Thiazolidinediones
    - HR (95% CI): 7.57e-03
    - P Value: 1.11e-01
Figure 4

(a) DPP4I

(b) SLGT2i

Comparisons

Effect of DPP4I and Metformin vs Metformin Only in T2D
Effect of DPP4I and Metformin vs no T2D
Effect of Metformin Only vs no T2D (identical no T2D as above)

P Values

9.47e-01
3.62e-01
4.32e-01
3.35e-02
3.78e-06
1.98e-02
Figure S1

a) Non T2Ds versus T2Ds
(by main ICD10 chapters)

<table>
<thead>
<tr>
<th>Causes of Death [ICD10 Chapter]</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certain infectious and parasitic diseases - ICD10 A00-B99</td>
<td>0.18</td>
</tr>
<tr>
<td>Neoplasms - ICD10 C00-D48</td>
<td>2.00e-20</td>
</tr>
<tr>
<td>Diseases of the blood - ICD10 D50-D99</td>
<td>2.00e-04</td>
</tr>
<tr>
<td>Endocrine, nutritional and metabolic diseases - ICD10 E00-E99</td>
<td>2.48e-57</td>
</tr>
<tr>
<td>Mental, Behavioral and Neurodevelopmental Diseases - ICD10 F00-F99</td>
<td>5.22e-09</td>
</tr>
<tr>
<td>Diseases of the nervous system - ICD10 G00-G99</td>
<td>0.72</td>
</tr>
<tr>
<td>Diseases of the ear and mastoid process - ICD10 H60-H99</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the circulatory system - ICD10 I00-I99</td>
<td>6.29e-13</td>
</tr>
<tr>
<td>Diseases of the respiratory system - ICD10 J00-J99</td>
<td>2.73e-30</td>
</tr>
<tr>
<td>Diseases of the digestive system - ICD10 K00-K99</td>
<td>1.62e-20</td>
</tr>
<tr>
<td>Diseases of the skin and subcutaneous tissue - ICD10 L00-L99</td>
<td>9.56e-03</td>
</tr>
<tr>
<td>Diseases of the musculoskeletal system - ICD10 M00-M99</td>
<td>0.34</td>
</tr>
<tr>
<td>Diseases of the genitourinary system - ICD10 N00-N99</td>
<td>1.95e-13</td>
</tr>
<tr>
<td>Abnormal clinical and laboratory findings - ICD10 R00-R99</td>
<td>1.00</td>
</tr>
<tr>
<td>Other special purpose codes non-COVID19 - ICD U00-U99</td>
<td>0.94</td>
</tr>
<tr>
<td>COVID19 - ICD10 U07.1</td>
<td>1.87e-76</td>
</tr>
</tbody>
</table>

b) Non T2Ds versus T2Ds
(by most frequent ICD10 subchapters)

<table>
<thead>
<tr>
<th>Causes of Death [ICD10 Subchapter]</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>[C15] Malignant neoplasm of oesophagus</td>
<td>0.51</td>
</tr>
<tr>
<td>[C16] Malignant neoplasm of colon</td>
<td>0.18</td>
</tr>
<tr>
<td>[C22] Malignant neoplasm of liver and intrahepatic bile ducts</td>
<td>4.10e-15</td>
</tr>
<tr>
<td>[C34] Malignant neoplasm of bronchus and lung</td>
<td>2.24e-03</td>
</tr>
<tr>
<td>[C50] Malignant neoplasm of breast</td>
<td>0.11</td>
</tr>
<tr>
<td>[C56] Malignant neoplasm of ovary</td>
<td>0.52</td>
</tr>
<tr>
<td>[C61] Malignant neoplasm of prostate</td>
<td>2.01e-05</td>
</tr>
<tr>
<td>[C71] Malignant neoplasm of brain</td>
<td>0.16</td>
</tr>
<tr>
<td>[C80] Malignant neoplasm without specification of site</td>
<td>0.03</td>
</tr>
<tr>
<td>[G30] Alzheimer's disease</td>
<td>7.64e-03</td>
</tr>
<tr>
<td>[I21] Acute myocardial infarction</td>
<td>6.02e-38</td>
</tr>
<tr>
<td>[I25] Chronic ischaemic heart disease</td>
<td>2.19e-75</td>
</tr>
<tr>
<td>[J44] Other chronic obstructive pulmonary disease</td>
<td>3.34e-09</td>
</tr>
<tr>
<td>[U071] COVID</td>
<td>7.02e-77</td>
</tr>
</tbody>
</table>
Figure S2 (continued)

<table>
<thead>
<tr>
<th>Medication</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin</td>
<td>400</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>40</td>
</tr>
<tr>
<td>DPP4i</td>
<td>38</td>
</tr>
<tr>
<td>Long/Interm.-Acting Insulins</td>
<td>811</td>
</tr>
<tr>
<td>SLGT2i</td>
<td>25</td>
</tr>
<tr>
<td>GLP1RA</td>
<td>14</td>
</tr>
<tr>
<td>Short-Acting Insulins</td>
<td>637</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>4</td>
</tr>
</tbody>
</table>

Individuals Using Anti-diabetic Drugs and not T2D [Counts]
Figure S5

a) T2D-Diagnosed only

<table>
<thead>
<tr>
<th>Covariates</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at recruitment</td>
<td>1.871e-77</td>
</tr>
<tr>
<td>Cancer</td>
<td>3.314e-08</td>
</tr>
<tr>
<td>Sex</td>
<td>3.185e-04</td>
</tr>
<tr>
<td>Other serious medical condition/disability</td>
<td>1.866e-13</td>
</tr>
<tr>
<td>Blood clots, DVT, bronchitis, emphysema</td>
<td>1.354e-05</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>2.261e-07</td>
</tr>
<tr>
<td>Fractured/broken bones</td>
<td>5.796e-01</td>
</tr>
<tr>
<td>Townsend deprivation index</td>
<td>9.900e-09</td>
</tr>
<tr>
<td>Sleep duration</td>
<td>9.939e-02</td>
</tr>
<tr>
<td>Body mass index</td>
<td>7.547e-03</td>
</tr>
<tr>
<td>Smoking</td>
<td>1.873e-22</td>
</tr>
<tr>
<td>Physical exercise</td>
<td>5.802e-03</td>
</tr>
<tr>
<td>Alcohol weekly units</td>
<td>6.871e-02</td>
</tr>
</tbody>
</table>

b) Matching Strategy between Cohorts of Type-2 Diabetics

<table>
<thead>
<tr>
<th>Priority-Matched Covariates</th>
<th>Comorbidities at Recruitment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline Characteristics</td>
<td>Age at recruitment</td>
</tr>
<tr>
<td></td>
<td>Sex</td>
</tr>
<tr>
<td>Other Matching Covariates</td>
<td>Other serious medical condition/disability</td>
</tr>
<tr>
<td></td>
<td>Blood clots, DVT, bronchitis, emphysema</td>
</tr>
<tr>
<td></td>
<td>Cardiovascular disorders</td>
</tr>
<tr>
<td>Other Comorbidities</td>
<td>Fractured/broken bones</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lifestyle Covariates</th>
<th>Diabetes Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Townsend deprivation index</td>
<td>Age at first use of anti-diabetic drug</td>
</tr>
<tr>
<td>Sleep duration</td>
<td></td>
</tr>
<tr>
<td>Body mass index</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
</tr>
<tr>
<td>Physical exercise</td>
<td></td>
</tr>
<tr>
<td>Alcohol weekly units</td>
<td></td>
</tr>
<tr>
<td>Other Matching Covariates</td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td></td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td></td>
</tr>
<tr>
<td>Long/Intermediate-acting insulin</td>
<td></td>
</tr>
<tr>
<td>DPP4I</td>
<td></td>
</tr>
<tr>
<td>SGLT2I</td>
<td></td>
</tr>
<tr>
<td>GLP1RA</td>
<td></td>
</tr>
<tr>
<td>Short-acting insulin</td>
<td></td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td></td>
</tr>
</tbody>
</table>

c) Non T2D-Diagnosed and T2D-Diagnosed

<table>
<thead>
<tr>
<th>Covariates</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at recruitment</td>
<td>0.001e+00</td>
</tr>
<tr>
<td>Cancer</td>
<td>6.613e-118</td>
</tr>
<tr>
<td>Sex</td>
<td>5.553e-23</td>
</tr>
<tr>
<td>Blood clots, DVT, bronchitis, emphysema</td>
<td>8.163e-31</td>
</tr>
<tr>
<td>Other serious medical condition/disability</td>
<td>2.287e-43</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>4.690e-24</td>
</tr>
<tr>
<td>Fractured/broken bones</td>
<td>1.359e-03</td>
</tr>
<tr>
<td>Townsend deprivation index</td>
<td>5.309e-54</td>
</tr>
<tr>
<td>Sleep duration</td>
<td>5.752e-04</td>
</tr>
<tr>
<td>Body mass index</td>
<td>1.208e-03</td>
</tr>
<tr>
<td>Smoking</td>
<td>4.272e-195</td>
</tr>
<tr>
<td>Physical exercise</td>
<td>4.588e-04</td>
</tr>
<tr>
<td>Alcohol weekly units</td>
<td>2.291e-01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HR (95% CI)</th>
<th>0.0</th>
<th>0.5</th>
<th>1.0</th>
<th>1.5</th>
<th>2.0</th>
<th>2.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>P Values</td>
<td>0.001</td>
<td>0.99</td>
<td>0.85</td>
<td>0.45</td>
<td>0.17</td>
<td>0.09</td>
</tr>
</tbody>
</table>

d) Matching Strategy between Non T2D-Diagnosed and T2D-Diagnosed

<table>
<thead>
<tr>
<th>Priority-Matched Covariates</th>
<th>Comorbidities at Recruitment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline Characteristics</td>
<td>Age at recruitment</td>
</tr>
<tr>
<td></td>
<td>Sex</td>
</tr>
<tr>
<td>Other Matching Covariates</td>
<td>Other serious medical condition/disability</td>
</tr>
<tr>
<td></td>
<td>Blood clots, DVT, bronchitis, emphysema</td>
</tr>
<tr>
<td></td>
<td>Cardiovascular disorders</td>
</tr>
<tr>
<td>Other Comorbidities</td>
<td>Fractured/broken bones</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lifestyle Covariates</th>
<th>Diabetes Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Townsend deprivation index</td>
<td>Age at first use of anti-diabetic drug</td>
</tr>
<tr>
<td>Sleep duration</td>
<td></td>
</tr>
<tr>
<td>Body mass index</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
</tr>
<tr>
<td>Physical exercise</td>
<td></td>
</tr>
<tr>
<td>Alcohol weekly units</td>
<td></td>
</tr>
<tr>
<td>Other Matching Covariates</td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td></td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td></td>
</tr>
<tr>
<td>Long/Intermediate-acting insulin</td>
<td></td>
</tr>
<tr>
<td>DPP4I</td>
<td></td>
</tr>
<tr>
<td>SGLT2I</td>
<td></td>
</tr>
<tr>
<td>GLP1RA</td>
<td></td>
</tr>
<tr>
<td>Short-acting insulin</td>
<td></td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td></td>
</tr>
</tbody>
</table>

e) Distance Metrics for Priority-Matched Quantitative Covariates

\[ e^{\frac{(\bar{x}_{T2DDrug} - \bar{x}_{control})^2}{0.5^2}} - 1 \]

f) Distance Metrics for Priority-Matched Binary Covariates

\[ e^{\sum_{i=1}^{n} \left| x_{T2DDrug} - x_{control} \right| - 1} \]
Figure S6 (continued)
Figure S7 (continued)

T2Ds only
(by most frequent ICD10 subchapters)

[16] Malignant neoplasm of colon
[22] Malignant neoplasm of liver and intrahepatic bile ducts
[23] Malignant neoplasm of pancreas
[34] Malignant neoplasm of bronchus and lung
[35] Malignant neoplasm of breast
[36] Malignant neoplasm of ovary
[61] Malignant neoplasm of prostate
[71] Malignant neoplasm of brain
[30] Malignant neoplasm without specification of site
[33] Alzheimer's disease
[21] Acute myocardial infarction
[25] Chronic ischemic heart disease
[44] Other chronic obstructive pulmonary disease

Proportion of Deaths in the Population [%]

P Values

Metformin
0.69
0.68
4.31e-02
3.99e-02
0.66
0.55
0.45
0.68
0.55
1.00
1.00
1.00
1.00
0.62
0.62
0.23
1.01e-02
0.20

DPP4I
1.00
1.00
1.00
0.63
0.42
1.00
1.00
1.00
0.25
2.42e-02
0.54
0.13
1.00

SLGT2I
1.00
1.00
1.00
0.50
0.25
1.30
1.00
1.00
1.00
0.79
0.25
0.58
Figure S8 (continued)

Non T2Ds versus T2Ds
(by main ICD10 chapters)

<table>
<thead>
<tr>
<th>Causes of Death [ICD10 Chapter]</th>
<th>Sulfonylureas</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certain infectious and parasitic diseases - ICD10 A00-A09</td>
<td>1.00</td>
<td>4.90e-03</td>
</tr>
<tr>
<td>Neoplasms - ICD10 C00-C04</td>
<td>0.46</td>
<td>7.63e-03</td>
</tr>
<tr>
<td>Diseases of the blood - ICD10 D50-D59</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Endocrine, nutritional and metabolic diseases - ICD10 E00-E99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Mental and behavioral disorders - ICD10 F00-F99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the nervous system - ICD10 G00-G99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the ear and mastoid process - ICD10 H60-H95</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the circulatory system - ICD10 I00-I99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the respiratory system - ICD10 J00-J99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the digestive system - ICD10 K00-K99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the skin and subcutaneous tissue - ICD10 L00-L99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the musculoskeletal system - ICD10 M00-M99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the genitourinary system - ICD10 N00-N99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Abnormal clinical and laboratory findings - ICD10 R00-R99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Other special purpose codes not COVID-19 - ICD10 U00-U99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>COVID-19 - ICD10 U07.1</td>
<td>1.00</td>
<td>4.64e-05</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Causes of Death [ICD10 Chapter]</th>
<th>Long/Intermediate-Acting Insulins</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certain infectious and parasitic diseases - ICD10 A00-A09</td>
<td>1.00</td>
<td>0.33</td>
</tr>
<tr>
<td>Neoplasms - ICD10 C00-C04</td>
<td>0.34</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the blood - ICD10 D50-D59</td>
<td>0.48</td>
<td>1.00</td>
</tr>
<tr>
<td>Endocrine, nutritional and metabolic diseases - ICD10 E00-E99</td>
<td>1.14e-03</td>
<td>1.00</td>
</tr>
<tr>
<td>Mental and behavioral disorders - ICD10 F00-F99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the nervous system - ICD10 G00-G99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the ear and mastoid process - ICD10 H60-H95</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the circulatory system - ICD10 I00-I99</td>
<td>4.96e-05</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the respiratory system - ICD10 J00-J99</td>
<td>0.20</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the digestive system - ICD10 K00-K99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the skin and subcutaneous tissue - ICD10 L00-L99</td>
<td>0.07</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the musculoskeletal system - ICD10 M00-M99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the genitourinary system - ICD10 N00-N99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Abnormal clinical and laboratory findings - ICD10 R00-R99</td>
<td>0.06</td>
<td>1.00</td>
</tr>
<tr>
<td>Other special purpose codes not COVID-19 - ICD10 U00-U99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>COVID-19 - ICD10 U07.1</td>
<td>3.09e-04</td>
<td>1.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Causes of Death [ICD10 Chapter]</th>
<th>GLP1RA</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certain infectious and parasitic diseases - ICD10 A00-A09</td>
<td>1.00</td>
<td>0.06</td>
</tr>
<tr>
<td>Neoplasms - ICD10 C00-C04</td>
<td>0.48</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the blood - ICD10 D50-D59</td>
<td>0.48</td>
<td>1.00</td>
</tr>
<tr>
<td>Endocrine, nutritional and metabolic diseases - ICD10 E00-E99</td>
<td>0.08</td>
<td>1.00</td>
</tr>
<tr>
<td>Mental and behavioral disorders - ICD10 F00-F99</td>
<td>0.48</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the nervous system - ICD10 G00-G99</td>
<td>0.45</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the ear and mastoid process - ICD10 H60-H95</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the circulatory system - ICD10 I00-I99</td>
<td>0.07</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the respiratory system - ICD10 J00-J99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the digestive system - ICD10 K00-K99</td>
<td>0.06</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the skin and subcutaneous tissue - ICD10 L00-L99</td>
<td>0.13</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the musculoskeletal system - ICD10 M00-M99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the genitourinary system - ICD10 N00-N99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Abnormal clinical and laboratory findings - ICD10 R00-R99</td>
<td>0.06</td>
<td>1.00</td>
</tr>
<tr>
<td>Other special purpose codes not COVID-19 - ICD10 U00-U99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>COVID-19 - ICD10 U07.1</td>
<td>0.13</td>
<td>1.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Causes of Death [ICD10 Chapter]</th>
<th>Short-Acting Insulins</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certain infectious and parasitic diseases - ICD10 A00-A09</td>
<td>1.00</td>
<td>0.04</td>
</tr>
<tr>
<td>Neoplasms - ICD10 C00-C04</td>
<td>0.44</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the blood - ICD10 D50-D59</td>
<td>0.48</td>
<td>1.00</td>
</tr>
<tr>
<td>Endocrine, nutritional and metabolic diseases - ICD10 E00-E99</td>
<td>0.39</td>
<td>1.00</td>
</tr>
<tr>
<td>Mental and behavioral disorders - ICD10 F00-F99</td>
<td>0.48</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the nervous system - ICD10 G00-G99</td>
<td>0.48</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the ear and mastoid process - ICD10 H60-H95</td>
<td>0.48</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the circulatory system - ICD10 I00-I99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the respiratory system - ICD10 J00-J99</td>
<td>4.76e-04</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the digestive system - ICD10 K00-K99</td>
<td>0.04</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the skin and subcutaneous tissue - ICD10 L00-L99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the musculoskeletal system - ICD10 M00-M99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the genitourinary system - ICD10 N00-N99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Abnormal clinical and laboratory findings - ICD10 R00-R99</td>
<td>0.07</td>
<td>1.00</td>
</tr>
<tr>
<td>Other special purpose codes not COVID-19 - ICD10 U00-U99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>COVID-19 - ICD10 U07.1</td>
<td>0.29</td>
<td>1.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Causes of Death [ICD10 Chapter]</th>
<th>Thiazolidinediones</th>
<th>P Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certain infectious and parasitic diseases - ICD10 A00-A09</td>
<td>1.00</td>
<td>0.06</td>
</tr>
<tr>
<td>Neoplasms - ICD10 C00-C04</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the blood - ICD10 D50-D59</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Endocrine, nutritional and metabolic diseases - ICD10 E00-E99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Mental and behavioral disorders - ICD10 F00-F99</td>
<td>0.48</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the nervous system - ICD10 G00-G99</td>
<td>0.07</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the ear and mastoid process - ICD10 H60-H95</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the circulatory system - ICD10 I00-I99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the respiratory system - ICD10 J00-J99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the digestive system - ICD10 K00-K99</td>
<td>0.25</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the skin and subcutaneous tissue - ICD10 L00-L99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the musculoskeletal system - ICD10 M00-M99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Diseases of the genitourinary system - ICD10 N00-N99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Abnormal clinical and laboratory findings - ICD10 R00-R99</td>
<td>0.07</td>
<td>1.00</td>
</tr>
<tr>
<td>Other special purpose codes not COVID-19 - ICD10 U00-U99</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>COVID-19 - ICD10 U07.1</td>
<td>0.25</td>
<td>1.00</td>
</tr>
</tbody>
</table>
Figure S8 (continued)

Non T2Ds versus T2Ds (by most frequent ICD10 subchapters)

**Metformin**

- P Values
  - 0.25
  - 0.63
  - 0.31
  - 3.07e-02
  - 1.00
  - 1.00
  - 0.77
  - 0.50
  - 0.10
  - 1.00
  - 0.00
  - 2.32e-02
  - 2.22e-02
  - 0.55
  - 1.16e-05

**DPP4I**

- P Values
  - 0.07
  - 1.00
  - 1.00
  - 0.42
  - 0.34
  - 0.29
  - 0.50
  - 0.13
  - 0.37
  - 1.00
  - 0.29
  - 1.00
  - 4.11e-02
  - 0.09

**SLGT2I**

- P Values
  - 0.07
  - 0.25
  - 1.00
  - 0.25
  - 0.62
  - 1.00
  - 1.00
  - 1.00
  - 1.00
  - 1.00
  - 1.00
  - 0.48
  - 0.48
  - 0.00
  - 0.49
  - 0.48

**Proportion of Deaths in the Population [%]**

- [C15] Malignant neoplasm of oesophagus
- [C16] Malignant neoplasm of colon
- [C22] Malignant neoplasm of liver and intrahepatic bile ducts
- [C25] Malignant neoplasm of pancreas
- [C34] Malignant neoplasm of bronchus and lung
- [C35] Malignant neoplasm of breast
- [C36] Malignant neoplasm of ovary
- [C61] Malignant neoplasm of prostate
- [C71] Malignant neoplasm of brain
- [C80] Malignant neoplasm without specification of site
- [D10] Alzheimer's disease
- [D21] Acute myocardial infarction
- [D25] Chronic ischaemic heart disease

**Proportion of Deaths in the Population [%]**

- [C15] Malignant neoplasm of oesophagus
- [C16] Malignant neoplasm of colon
- [C22] Malignant neoplasm of liver and intrahepatic bile ducts
- [C25] Malignant neoplasm of pancreas
- [C34] Malignant neoplasm of bronchus and lung
- [C35] Malignant neoplasm of breast
- [C36] Malignant neoplasm of ovary
- [C61] Malignant neoplasm of prostate
- [C71] Malignant neoplasm of brain
- [C80] Malignant neoplasm without specification of site
- [D10] Alzheimer's disease
- [D21] Acute myocardial infarction
- [D25] Chronic ischaemic heart disease

**Proportion of Deaths in the Population [%]**

- [C15] Malignant neoplasm of oesophagus
- [C16] Malignant neoplasm of colon
- [C22] Malignant neoplasm of liver and intrahepatic bile ducts
- [C25] Malignant neoplasm of pancreas
- [C34] Malignant neoplasm of bronchus and lung
- [C35] Malignant neoplasm of breast
- [C36] Malignant neoplasm of ovary
- [C61] Malignant neoplasm of prostate
- [C71] Malignant neoplasm of brain
- [C80] Malignant neoplasm without specification of site
- [D10] Alzheimer's disease
- [D21] Acute myocardial infarction
- [D25] Chronic ischaemic heart disease

**Proportion of Deaths in the Population [%]**

- [C15] Malignant neoplasm of oesophagus
- [C16] Malignant neoplasm of colon
- [C22] Malignant neoplasm of liver and intrahepatic bile ducts
- [C25] Malignant neoplasm of pancreas
- [C34] Malignant neoplasm of bronchus and lung
- [C35] Malignant neoplasm of breast
- [C36] Malignant neoplasm of ovary
- [C61] Malignant neoplasm of prostate
- [C71] Malignant neoplasm of brain
- [C80] Malignant neoplasm without specification of site
- [D10] Alzheimer's disease
- [D21] Acute myocardial infarction
- [D25] Chronic ischaemic heart disease

**Proportion of Deaths in the Population [%]**

- [C15] Malignant neoplasm of oesophagus
- [C16] Malignant neoplasm of colon
- [C22] Malignant neoplasm of liver and intrahepatic bile ducts
- [C25] Malignant neoplasm of pancreas
- [C34] Malignant neoplasm of bronchus and lung
- [C35] Malignant neoplasm of breast
- [C36] Malignant neoplasm of ovary
- [C61] Malignant neoplasm of prostate
- [C71] Malignant neoplasm of brain
- [C80] Malignant neoplasm without specification of site
- [D10] Alzheimer's disease
- [D21] Acute myocardial infarction
- [D25] Chronic ischaemic heart disease

**Proportion of Deaths in the Population [%]**

- [C15] Malignant neoplasm of oesophagus
- [C16] Malignant neoplasm of colon
- [C22] Malignant neoplasm of liver and intrahepatic bile ducts
- [C25] Malignant neoplasm of pancreas
- [C34] Malignant neoplasm of bronchus and lung
- [C35] Malignant neoplasm of breast
- [C36] Malignant neoplasm of ovary
- [C61] Malignant neoplasm of prostate
- [C71] Malignant neoplasm of brain
- [C80] Malignant neoplasm without specification of site
- [D10] Alzheimer's disease
- [D21] Acute myocardial infarction
- [D25] Chronic ischaemic heart disease

**Proportion of Deaths in the Population [%]**

- [C15] Malignant neoplasm of oesophagus
- [C16] Malignant neoplasm of colon
- [C22] Malignant neoplasm of liver and intrahepatic bile ducts
- [C25] Malignant neoplasm of pancreas
- [C34] Malignant neoplasm of bronchus and lung
- [C35] Malignant neoplasm of breast
- [C36] Malignant neoplasm of ovary
- [C61] Malignant neoplasm of prostate
- [C71] Malignant neoplasm of brain
- [C80] Malignant neoplasm without specification of site
- [D10] Alzheimer's disease
- [D21] Acute myocardial infarction
- [D25] Chronic ischaemic heart disease